BD Response Plan on COVID-19 (Coronavirus) Show sub-menu BD Response Plan on COVID-19 (Coronavirus) Support resources Emerging stronger, together For the healthcare community. For patients. For all. All of us are striving to navigate the uncertainty of the COVID-19 pandemic. As the current healthcare focus is on delivering COVID-19 vaccinations, administering rapid and accurate diagnosis and providing optimal patient care, we are leveraging our expertise and global reach to provide support and continued access to critical healthcare products. With unwavering commitment, we stand united with you—now and into the future. Download a copy of the BD Statement on COVID-19 (Coronavirus) Critical ways we can help you Rapid COVID-19 testing Explore COVID-19 PCR testing Explore COVID-19 vaccination preparedness Explore Our responsibility in a time of crisis Explore COVID-19 urgent response stories View videos Supporting supply continuity Our multiple domestic manufacturing facilities and extensive supplier base provide supply continuity for you and uninterrupted care for your patients. Order status lookup Order status, order tracking, delivery confirmation and estimated delivery dates Check the status of my order » List of products Up-to-date lists of products on manual inventory allocation View inventory » COVID-19 patient care support across the continuum As one of the largest global medical technology companies in the world, BD is deploying our capabilities, expertise and scale to address critical health needs related to coronavirus—from our diagnostic offerings to identify COVID-19, to real-time informatics and electronic surveillance technology, to essential medical devices to support patient care. See how Product training, education and clinical resources Vascular access and medication delivery » Response and support resources Biosciences solutions » Solutions to enable COVID-19 research Medication management solutions » Resources and FAQs Peripheral arterial disease, end stage kidney disease and oncology » Patient management resources COVID-19 insights designed to quantify national* trends *U.S. only Learn more Infection control training from the Society for Healthcare Epidemiology of America (SHEA) and BD Reinforce appropriate infection prevention and control behaviors with the Prevention Course in HAI Knowledge and Control (Prevention CHKC). Sign up COVID-19 blogs View posts COVID-19 news View news BD Statement on COVID-19 (Coronavirus) Updated June 2021 BD continues to closely monitor COVID-19 (coronavirus) developments across the world as well as guidance from the U.S. Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and global health officials. We are working vigilantly to protect the health and safety of BD employees while also ensuring continued availability of BD’s critical health-preserving, life-saving and diagnostic medical devices during this challenging time. Status of BD operations and supply chain BD manufactures and sources product from multiple locations around the world. All of our global manufacturing and distribution centers are operational at this time, with the vast majority of critical-to-COVID sites operating at or near full capacity. In countries where local governments have imposed stricter “lockdown” measures to slow the spread of coronavirus, BD facilities continue to operate with measures in place to ensure business continuity and minimize risk of disruption to our customers. BD continues to work closely with our key suppliers around the world that provide raw materials and components to BD manufacturing plants. We have implemented business continuity measures to mitigate the risk of potential supplier disruption, including partnering with local governments to seek “essential business” exemptions for key suppliers where necessary. BD continues to have sufficient raw material and component inventory for the majority of products considered critical-to-COVID. Where materials or components are deemed at risk, BD activates any number of pre-approved contingency plans, including those for: Increased safety stock and expedited air shipments Seeking alternative suppliers Redeploying raw materials and/or finished goods from other parts of the BD network Placing at-risk products on customer allocation to prevent stockpiling. Dedicated teams continue to actively monitor our global logistics and transportation network, taking action when necessary to navigate global capacity limitations and border constraints to minimize the risk of any customer delays. We are making every effort to ensure final product is transported to distributors and customers as quickly and efficiently as possible. Product availability For U.S. customers, an up-to-date list of products on manual inventory allocation can be found at bd.com/allocation. Employee safety BD continues to follow all state, local and federal requirements and ensure adherence to work site health and safety regulations for our essential workers. We have instituted preventative measures at our facilities to help protect employees in accordance with the CDC and government regulations. We will continue to adjust safety protocols in line with these regulations and new science emerging about virus transmission and vaccine effectiveness. Supporting global response As one of the largest global medical technology companies in the world, BD is deploying our capabilities, expertise and scale to address critical health needs related to coronavirus – from our diagnostic offerings to detect SARS-CoV-2, to real-time informatics and electronic surveillance technology, to essential medical devices to support patient care. Specifically, BD: Has committed 2 billion needles and syringes to support global COVID-19 vaccination planning efforts in more than 40 countries and delivered shipments of more than 900 million injections devices around the world. Is partnering with USA Swimming to provide COVID-19 screening for the Olympic Trials and other competitive swimming events. Has announced, along with CerTest Biotec, the VIASURE SARS-CoV-2 (N1 + N2) real time PCR detection kit for the BD MAX™ Molecular Diagnostic System that can now be run on saliva specimens. Is partnering with USA Track & Field to provide rapid COVID-19 testing to enhance athlete safety at track & field events. Has received Emergency Use Authorization for asymptomatic screening for SARS-CoV-2 through serial rapid antigen testing. Is offering a new, rapid antigen test that can detect SARS-CoV-2, influenza A and influenza B in a single test. Is preparing for future pandemic efforts by partnering with the U.S. government on a $70 million capital project to further expand BD's operations and manufacturing capacity in Nebraska that, when complete, will provide the federal government with priority access to hundreds of millions of injection devices to support vaccination efforts for COVID-19 and future pandemics. Is investing approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes and advanced drug delivery systems to allow for continued growth of new injectable drugs and vaccines and provide surge capacity for increased pre-fillable syringe demand during times of pandemic response. In addition, BD and the BD Foundation have issued nearly $2.8 million in philanthropic grants and product donations to trusted non-profit partners that are working to protect the most vulnerable communities and individuals from the pandemic’s spread and negative impacts. BD volunteers are heeding the call, too. Clinically trained associates in BD sites around the world have volunteered their time to augment hospital staff in communities hard-hit by COVID-19; and, associates from a broad range of disciplines have delivered virtual trainings to teach community and non-profit organizations how to contain its spread. For more on BD’s response efforts, visit our video library. OFFERINGS Brands Capabilities Catalogs Integrated solutions COMPANY BD code of conduct Careers Contact us Cybersecurity External Funding Program Inclusion and Diversity Investors News Suppliers Sustainability Video gallery CLINICAL EXCELLENCE Case studies Events Training Webcasts SUPPORT Alerts and notices COVID-19 Customer portals Electronic Instructions for Use Live chat Order status Technical support Website accessibility facebook twitter linkedin youtube © 2021 BD. All rights reserved. BD and the BD Logo are trademarks of Becton, Dickinson and Company. All other trademarks are the property of their respective owners. Privacy | Terms of Use | Cookies Settings By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Accept All Cookies